Stock Market News
Latest financial news · Updated Jul 11, 2026
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
The panel is largely bearish on Viking Therapeutics' (VKTX) obesity drug VK2735, citing potential challenges in commercialization, manufacturing scale, and …
Didn't Get Shares on SpaceX's IPO Day? Here's How Investors Can Increase Their Exposure.
The panel consensus is bearish on indirect SpaceX exposure through ARKX and suppliers due to dilution risk, lack of liquidity, …
You Retired This Year. Medicare Is Charging You Off the Six-Figure Salary You Earned in 2024
The panel agrees that the SSA-44 mechanism for IRMAA relief is complex, uncertain, and may not provide the expected benefits …
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
The panel is divided on AbbVie's acquisition of Apogee, with concerns about execution risk, competition, and near-term dilution outweighing the …
Should You Buy Moderna Before Aug. 5?
The panel is bearish on Moderna's (MRNA) near-term prospects, with the FDA approval of mRNA-1010 on Aug. 5 being largely …
Meta Appoints Kunal Shah As WhatsApp Leader
Meta's appointment of Kunal Shah to lead WhatsApp India signals a strategic push into payments and commerce, leveraging his fintech …
Do you know your 'sweat score'? The rise of hydration tech
The panel consensus is bearish on the hydration tech market, citing weak independent validation, unproven ROI, regulatory scrutiny, consumer fatigue, …
Is It Too Late to Buy SpaceX Stock?
The panel largely agrees that SpaceX's current valuation is unsustainable, with key risks including capital intensity, competition, and regulatory hurdles. …
NHTSA Opens Investigation Into Fatal Tesla Crash In Texas
The panel consensus is that the NHTSA's investigation into Tesla's Autopilot/FSD poses a significant risk, potentially leading to regulatory oversight, …
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
The panel is largely bearish on AbbVie's acquisition of Apogee, citing regulatory risks, clinical trial uncertainties, and aggressive valuation.
Tesla faces federal probe after Model 3 slams into Texas home, killing 76-year-old
The panel consensus is that the ongoing NHTSA probe into Tesla's Autopilot/FSD systems poses a significant risk to the company's …
SpaceX Is Buying Cursor for $60 Billion. What That Means for SPCX Stock.
The panel consensus is bearish on the proposed SpaceX takeover of Cursor, citing integration risks, regulatory hurdles, data privacy concerns, …